Type 2 Diabetes Medication Flashcards
7 drugs types
- metformin
- sulphonyureas
- thiazolidones
- DDP-IV inhibitor
- SGLT-2 inhibitor
- GLP-1 agonist
- insulin
mechanism of metformin
acts on liver and muscle to improve insulin receptor sensitivity, stimulate glucose breakdown and inhibit gluconeogenesis
3 ways in which metformin improves insulin receptor sensitivity
improves receptor function, reduces fatty acid synthesis and improve glucose transport
side effects of metformin
GI problems, B12 malabsorption and lactic acidosis
pros of metformin
cheap, well tolerated, no weight gain, good for CV
drugs with risk of hypos
sulphonylureas and insulin
mechanism of sulphonylureas
binds to receptors on b-cells to close K+ channels and stimulate insulin exocytosis
site of sulphonylureas action
pancreas
side effects of sulphonylureas
weight gain, hypos, not good for renal or liver disease
when are sulphonylureas indicated as a 1st line
when there is concern of weight loss or osmotic symptoms?
what are the other 2nd line options for when weight gain, hypos and renal/liver disease are present
thiazolidinedione
DPP-IV inhibitor
SGLT-2 inhibitor
which 2 drugs are only 3rd line options
GLP-1 agonist and insulin
mechanism of thiazolidiones action
activated PPAR-ϒ gene in liver, muscle and fat to reduce free fatty acids and insulin resistance
true/false thiazolidiones lower HbA1c by ~1%
true - not very much compared to metformin’s 12-17%
true/false sulphonylureas can be used in pregancy and breastfeeding
false - it’s contraindicated
true/false metformin can be used in pregnancy and breastfeeding
true
side effects of thiazolidiones
weight gain, congestive cardiac failure, bladder cancer, fractures
what test is set as a target marker in treatment
HbA1c
true/false you would prescribe thiazolidinedione when there is a concern of congestive heart failure
false - thiazolidinedione causes fluid retention and then congestive cardicat failure.
give sulphonylurea, DPP-IV inhibitor or SGLT-2 inhibitor
when are DPP-IV inhibitors indicated
when 1st line isn’t cutting the mustard and there is concern of weight gain, CCF or hypos
mechanism of DPP-IV inhibitors
the DPP-4 enzyme breaks down incretins. Incretins are gut hormones that stimulate insulin release and inhibit glucagon.
therefore inhibit DPP-4 and you increase insulin release